- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
Positive top line results from ALX-0171 infant RSV study
4 May 2016 • Author: Victoria White, Digital Content Producer
Ablynx has announced positive top line results from the first-in-infant Phase I/IIa study of its anti-RSV Nanobody, ALX-0171.
ALX-0171 was used to treat 53 infants, aged 1-24 months, hospitalised as a result of a respiratory syncytial virus (RSV) infection. The study consisted of an open-label lead-in phase with 5 infants, aged 5-24 months who received the therapy and a double-blind, placebo-controlled phase with 48 infants, aged 1-24 months, who were randomised to ALX-0171 or placebo. The primary endpoint of the study was the assessment of safety and tolerability for once daily inhalation of ALX-0171 for three consecutive days. Secondary endpoints included assessments of clinical effect (including effect on feeding, oxygen saturation, respiratory rate, wheezing, coughing and general appearance), immunogenicity, pharmacokinetics and pharmacodynamics of inhaled ALX-0171.
The study met its primary endpoint, demonstrating the favourable safety and tolerability profile of ALX-0171 when administered daily by inhalation in the target infant population, with no treatment-related serious adverse events reported.
ALX-0171 was detected in the serum of subjects after treatment, consistent with lung exposure. Anti-drug antibodies had no effect on the pharmacokinetics and no relation with adverse events was seen.
ALX-0171 had an immediate impact on viral replication
Treatment with the inhaled therapy had an immediate impact on viral replication and also reduced viral load, as compared to placebo. Analysis of a composite of clinical efficacy endpoints, the Global Severity Score, led to an encouraging initial indication of a therapeutic effect for infants treated with ALX-0171.
Commenting on the results, Dr Robert K. Zeldin, CMO of Ablynx, said: “We believe we are pioneers in the development of a treatment for infants infected with RSV, an area of significant unmet medical need. We are very pleased that the positive safety and tolerability profile of our inhaled Nanobody observed in adults has now been confirmed in this vulnerable target population. In addition, we demonstrated ALX-0171’s marked antiviral effect in RSV-infected infants and saw encouraging initial signs of clinical efficacy. We believe these results strongly support advancement into a Phase II efficacy study in infants.”
Dr Steve Cunningham, Department of Respiratory and Sleep Medicine, Royal Hospital for Sick Children, Edinburgh, UK, and Principle Investigator of the study, added: “There is no effective therapy available at present and the positive outcome from Ablynx’s first-in-infant study is therefore an important step forward in the development of an effective therapeutic for this serious infection.”
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) EUROGENTEC F.P.S. Food and Pharma Systems Srl IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics